Graybug Vision Inc is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.
The company stated in the following news article that they use animals for product testing.
“Two-year animal data support the potential for GB-501 to cure corneal clouding and restore vision in MPS1 patients. All patients required for the Phase 1/2a trial have been identified, IND submission is expected in the second quarter of 2023, and the data readout is expected in the fourth quarter of 2023.” Read the following article
Graybug Vision, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The Company’s lead product candidate, GB-102, is an intravitreal injection of a microparticle depot formulation of sunitinib, an inhibitor of neovascular growth and permeability, which are causes of retinal disease.
Company Website: https://www.graybug.vision